Report Preview

Bulimia Nervosa Treatment Market

The global bulimia nervosa treatment market size was valued at USD 500 million in 2021 and is projected to reach around USD 800 million in 2030 exhibiting a CAGR of 5.0% in the forecasted period. The increasing prevalence of eating disorders in geriatric population, augmented research and development for increasing advanced therapies are anticipated to drive the global bulimia nervosa treatment market revenue growth. However, presence of only less genuine and approved medicines for treatment of bulimia nervosa is the major factor hindering revenue growth of the bulimia nervosa treatment market.

There are numerous factors that are helping in revenue growth of the bulimia nervosa treatment market. The foremost factor is growing prevalence of bulimia nervosa. Bulimia nervosa had a lifetime prevalence of 1.0% adults had a 0.3% overall occurrence of bulimia nervosa. Females (0.5%) had a five times greater prevalence of bulimia nervosa than males (0.1%). The patients have to face a lot of damages in their lifestyle and that are treated by the medicines available in the market that is helping in revenue growth of the bulimia nervosa treatment market. As per the Sheehan Disability Scale based on behaviour from the earlier year, 43.9% of those with bulimia nervosa had a severe injury and 78.0% had any disability. Additionally, the symptomatic treatment by antidepressants is assisting in inhibiting various patients from impediments of bulimia nervosa. From 2015 to 2018, around 13.2% of adults used antidepressants. Use was more widespread among women (17.7%) than men (8.4%). Antidepressant use rose with age, from 7.9% among those aged 18 to 39 to 14.4% for those in the 40 to 59 age to 19.0% for those in the 60 and beyond. These are the factors backing to revenue growth of the bulimia nervosa market.

The COVID-19 epidemic is anticipated to disturb the global market for the treatment of bulimia nervosa throughout the forecasted period. As per the Indian Journal of Medical Sciences, on June 6, 2020, the COVID-19 epidemic affected the conduct of clinical trials owing to absence of travel restrictions, laboratory staff, accessibility of research products, and more. These problems are complications to increasing managements for bulimia nervosa.

As per the National Center for Biotechnology Information (NCBI), on August 24, 2020, due to the COVID-19 epidemic, the government enforced limitations on several parts of the globe. This has intended to the failure of all industries, which has been a force to upsurge joblessness. Moreover, deficiency of communication has led to increasing feelings of anxiety and depression. For example, as per the Center for Disease Control and Prevention (CDC), on April 4, 2020, instances of depression in the US have tripled through the COVID-19 epidemic compared to 2019, the reasons of bulimia nervosa, amongst people.

Disease Type Insights

Based on the disease type, the global bulimia nervosa treatment market is bifurcated into purging and non-purging. The purging segment is anticipated to boost the market growth in the estimated period. The factors affecting the market growth are increasing prevalence of purging among the young adults, especially women. For example, as per an article issued in the National Center for Biotechnology Information (NCBI), 2016, purging behaviours are most common in young adult women, with public point occurrence estimates of any purging ranging up to 2.1% in women and up to 1% in men. Lifespan approximations of purging behaviours are higher, with up to 16.5% of women and 3.3% of men authorizing purging in their lifetime.

End User Insights

Based on end user, the global bulimia nervosa treatment market is segmented into hospitals, speciality clinics, homecare, and others. Due to the increasing patient population, the hospital’s segment held the prominent market share. This is mostly due to the rising number of patients suffering from bulimia nervosa treatment that are treated in hospitals with advanced structure and adequate services. Additionally, the rising number of hospitals along with proper reimbursement policies is also donating to the growth of this segment.

Region Insights

North America is anticipated to account for leading revenue share during the forecasted period. This is owing to introduction of new treatment selections in the region. Additionally, augmented healthcare expenditures, as well as accessibility of treatment choices, would help boost revenue growth of the market in the region. Likewise, increasing awareness of the disease has led to revenue growth of the market. These factors are projected to drive revenue growth of the bulimia nervosa market in the region during the forecast period.

Asia Pacific is likely to register a significant CAGR over the estimated period. In nations such as China and India, there is a substantial increase in the elderly population. Moreover, revenue growth in the region is compelled by presence of generic companies along with growth of healthcare facilities in the region. These key factors are anticipated to boost revenue growth of the market over the forecasted period.

Key Companies Insights

The market for bulimia nervosa treatment is moderately competitive. With the rising applications of bulimia nervosa treatment, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the bulimia nervosa treatment market, ultimately boosting the market growth. Some of the key companies working in the global bulimia nervosa treatment market include:

• AstraZeneca plc
• Sun Pharmaceutical Industries Ltd
• GSK plc
• Eli Lilly & Company
• Bayer AG
• Zydus Cadila
• Reddy’s Laboratories Limited
• Pfizer Inc.
• Sorrento Therapeutics, Inc.
• Johnson & Johnson
• Lupin limited
• Other players

Some of the Recent Developments:

• In 2019, India-based pharmaceutical company, Lupin Limited, launched generic version of Fluoxetine tablet with strengths of 20 mg and 10 mg. Fluoxetine is an antidepressant, and this new product can be used for the treatment of bulimia nervosa.
• In 2019, two of the U.S.-based topmost eating disorder support organizations, the National Eating Disorders Association (NEDA) and the National Association for Males with Eating Disorders (NAMED), have combined to support the eating disorders community and upsurge entrance to services and backing for people with eating disorders of all categories. The joint company will go by the name NEDA.

Segments

By Treatment Type

• Antidepressants
• Antipsychotics
• Selective serotonin reuptake inhibitor
• Serotonin-norepinephrine reuptake inhibitor
• Benzodiazepines
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Disease Type

• Purging
• Non-purging

By End User

• Hospitals
• Speciality Clinics
• Homecare
• Others

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt